As a follow-up to the RAPIDIRON Trial (NCT05358509), this study will follow the previously randomized mothers as well as their offspring after birth to assess neurodevelopmental, hematologic, and health outcomes. The study's overarching goal is to determine if the offspring born to RAPIDIRON Trial mothers in the intravenous iron groups, compared to the oral iron group, will achieve superior neurodevelopment, iron stores, and growth at specific time points during the first three years of life. Differences will be assessed between offspring based on the iron deficiency anemia (IDA) treatment of the mother.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Offspring hemoglobin
Timeframe: Birth
Offspring hemoglobin
Timeframe: 4 months of age
Offspring ferritin
Timeframe: Birth
Offspring ferritin
Timeframe: 4 months of age
Cognitive Domain of Bayley Scales of Infant Development (BSID)
Timeframe: 24 months of age